Global Infusion Devices Market Set To Grow To $12.3bn By 2022

06 August 2018
Pharma

Visiongain’ has launched a new pharma report Global Infusion Devices Market Forecast to 2027: Infusion Pumps, Insulin Pumps, Enteral Feeding Pumps, other Infusion Pumps
Infusion pumps have been a reliable source of drug delivery for nearly a century. These infusion devices can be used to treat a wide range of therapeutic areas including analgesia, chemotherapy, diabetes and clinical nutrition, thus making them an invaluable tool in modern medicine. With the advent of modern medical devices the infusion pump market has become one of the fastest growing drug delivery segments within the market. This rapid growth is projected due to the nature of the illnesses which infusion pumps are used to treat.

The lead analyst of the report commented “Visiongain has identified several issues and trends impacting the future of the infusion pumps market. Ageing populations, increasing incidence of diseases - particularly diabetes, and increasing healthcare coverage in developing countries will continue to fuel market growth in the future.

Key issues and trends explored in this report include: increasing life expectancy worldwide, growing incidence of disease, worldwide spending on healthcare, infusion pump health risks and recalls, new regulations in leading national markets, smart pump technology and a shift from hospital to home health care.”

Leading companies featured in the report include ALCOR Scientific, Altea Therapeutics, Animas Corporation, B.Braun, Baxter, CareFusion, Cellnovo, Covidien, D. Medical Industries, Danone Nutricia, Debiotech, Disetronic (Roche), Fresenius Kabi, Hospira, Insulet CorporationJohnson & Johnson, Medline, MedSolve Technologies, Medtronic, Q Core Medical, Roche, Smiths Medical
SOOIL, Tandem Diabetes Care, Valeritas, Zevex

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Generic Drugs market set to grow to $424bn by 2024” says new Visiongain report

Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.

14 June 2019

Read

“Global Precision Cancer Diagnostic Tests market set to grow to $21.3bn by 2024” says new Visiongain report

The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously.

06 June 2019

Read

“Global Antifungal Drugs market set to grow to $17bn by 2024” says new Visiongain report

Market penetration and adoption of new technologies entering the market for antifungal drugs will be crucial for market growth.

04 June 2019

Read

“Global Ophthalmic Equipment market set to grow to $75bn by 2024” says new Visiongain report

here is a growing demand for ophthalmic equipment such as vision care products and ophthalmology surgical devices, mainly due to the increasing incidence of myopia across the world.

03 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever